会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Netrin-1 compositions and methods of use thereof
    • Netrin-1组合物及其使用方法
    • US08524228B2
    • 2013-09-03
    • US12740594
    • 2008-11-03
    • Wen-Cheng XiongJae-Ho LeeLin Mei
    • Wen-Cheng XiongJae-Ho LeeLin Mei
    • A61K39/395A61K39/00C07K16/22
    • A61K38/18G01N33/689G01N2333/475G01N2800/367
    • Methods and compositions for male or female contraception are provided. The compositions include an effective amount of netrin-1 to reduce or inhibit sperm concentration in semen of males or to inhibit or reduce fusion of male gametes with female gametes in a female subject Still another embodiment provides a method for diagnosing male infertility by determining the amount of netrin-1 in a sample of epididymal fluid or semen from a male subject, comparing the amount of netting-1 in the sample to levels of netrin-1 in samples of epididymal fluid or semen from fertile males, wherein levels of netrin-1 in the sample from the male subject that are higher or lower than levels of netrin-1 in samples from fertile males are indicative of male infertility in the male subject.
    • 提供男性或女性避孕方法和组合物。 组合物包括有效量的netrin-1以减少或抑制雄性精液中的精子浓度或抑制或减少雄性配子与女性受试者的雌性配子的融合。另一个实施方案提供了一种通过确定雌性不育症的量来确定男性不育症的量 的netrin-1在附睾液或精液样本中的比较,将来自可能的男性的附睾液或精液样品中的netting-1与netrin-1的水平进行比较,其中netrin-1 在男性受试者的样本中,来自可育男性样本中的netrin-1水平高于或低于男性受试者的男性不育症。
    • 6. 发明授权
    • Methods and compositions for modulating ErbB2 activity
    • 调节ErbB2活性的方法和组合物
    • US08461114B2
    • 2013-06-11
    • US12780065
    • 2010-05-14
    • Lin MeiYanmei TaoWen-Chen Xiong
    • Lin MeiYanmei TaoWen-Chen Xiong
    • A61K38/00
    • C07K14/4702C07K16/32C07K2317/76C12N15/113C12N2310/14
    • Modulating the interaction between ErbB2 and Erbin is an effective method for treating one or more symptoms of ErbB2-mediated disorders. It has been discovered that Erbin stabilizes ErbB2 in vivo and inhibiting the formation of heterodimers between Erbin and ErbB2 reduces or inhibits the biological activity of ErbB2 relative to control levels. Reducing the biological activity of ErbB2 is useful in the treatment of conditions characterized by the overexpression or misregulation of ErbB2. These conditions include, but are not limited to breast cancer and prostate cancer. Alternatively, agonist of Erbin that promote or enhance the interaction of Erbin with ErbB2 can be useful in the treatment of certain neurological disorders. It has also been discovered that Erbin plays a role in the myelination of neurons of the peripheral nervous system.
    • 调节ErbB2和Erbin之间的相互作用是治疗ErbB2介导的疾病的一种或多种症状的有效方法。 已经发现Erbin在体内稳定ErbB2并且抑制Erbin和ErbB2之间异源二聚体的形成相对于对照水平降低或抑制ErbB2的生物学活性。 降低ErbB2的生物活性可用于治疗以ErbB2的过表达或失调为特征的病症。 这些病症包括但不限于乳腺癌和前列腺癌。 或者,促进或增强Erbin与ErbB2相互作用的Erbin激动剂可用于治疗某些神经障碍。 还发现Erbin在周围神经系统神经元的髓鞘形成中起作用。
    • 7. 发明申请
    • Methods and Compositions for Modulating ERBB2 Activity
    • 调节ERBB2活性的方法和组合
    • US20100291077A1
    • 2010-11-18
    • US12780065
    • 2010-05-14
    • Lin MeiYanmei TaoWen-Chen Xiong
    • Lin MeiYanmei TaoWen-Chen Xiong
    • A61K39/395C12N5/02A61P35/00
    • C07K14/4702C07K16/32C07K2317/76C12N15/113C12N2310/14
    • Modulating the interaction between ErbB2 and Erbin is an effective method for treating one or more symptoms of ErbB2-mediated disorders. It has been discovered that Erbin stabilizes ErbB2 in vivo and inhibiting the formation of heterodimers between Erbin and ErbB2 reduces or inhibits the biological activity of ErbB2 relative to control levels. Reducing the biological activity of ErbB2 is useful in the treatment of conditions characterized by the overexpression or misregulation of ErbB2. These conditions include, but are not limited to breast cancer and prostate cancer. Alternatively, agonist of Erbin that promote or enhance the interaction of Erbin with ErbB2 can be useful in the treatment of certain neurological disorders. It has also been discovered that Erbin plays a role in the myelination of neurons of the peripheral nervous system.
    • 调节ErbB2和Erbin之间的相互作用是治疗ErbB2介导的疾病的一种或多种症状的有效方法。 已经发现Erbin在体内稳定ErbB2并且抑制Erbin和ErbB2之间异源二聚体的形成相对于对照水平降低或抑制ErbB2的生物学活性。 降低ErbB2的生物活性可用于治疗以ErbB2的过表达或失调为特征的病症。 这些病症包括但不限于乳腺癌和前列腺癌。 或者,促进或增强Erbin与ErbB2相互作用的Erbin激动剂可用于治疗某些神经障碍。 还发现Erbin在周围神经系统神经元的髓鞘形成中起作用。
    • 9. 发明授权
    • Method for characterizing a perpendicular recording head writing pole
    • 用于表征垂直记录头书写杆的方法
    • US06969989B1
    • 2005-11-29
    • US11078266
    • 2005-03-11
    • Lin Mei
    • Lin Mei
    • G11B5/127G11B5/187G11B5/455
    • G11B5/1278
    • A method characterizes a generally-trapezoidally-shaped portion of a writing pole of a perpendicular magnetic write head in proximity to a magnetic medium. The method includes providing measured track width data corresponding to magnetic track widths of a plurality of tracks written by the writing pole on a rotating magnetic medium underlying the writing pole. The magnetic track widths vary as a function of skew angle of the writing pole during writing. The method further includes determining a magnetic width of the wider of a leading edge and a trailing edge of the writing pole from a first portion of the measured track width data corresponding to a first range of skew angles. The method further includes determining at least one magnetic taper angle of the writing pole from the measured track width data.
    • 一种方法表征垂直磁性写头的书写极的大致梯形部分,靠近磁介质。 该方法包括提供对应于写字杆写入的多个轨道的磁道宽度的测量的轨道宽度数据在书写杆下方的旋转磁介质上。 磁道宽度随写入时写字杆的倾斜角度而变化。 所述方法还包括从对应于第一偏斜角范围的所测量的轨道宽度数据的第一部分确定写入极的前边缘和后边缘的较宽的磁宽度。 所述方法还包括根据所测量的轨道宽度数据确定书写杆的至少一个磁锥角。
    • 10. 外观设计
    • LED saber
    • USD990585S1
    • 2023-06-27
    • US29859130
    • 2022-11-08
    • Lin Mei
    • Lin Mei
    • FIG. 1 is a front and right perspective view of a LED saber, showing my new design;
      FIG. 2 is a rear, left, and bottom perspective view thereof;
      FIG. 3 is a front elevational view thereof;
      FIG. 4 is a rear elevational view thereof;
      FIG. 5 is a left elevational view thereof;
      FIG. 6 is a right elevational view thereof;
      FIG. 7 is a top plan view thereof;
      FIG. 8 is a bottom plan view thereof;
      FIG. 9 is an enlarged view of the delineated region 9 in FIG. 1; and,
      FIG. 10 is an enlarged view of the delineated region 10 in FIG. 1.
      The dot-dash broken lines in FIGS. 1, 9, and 10 form no part of the claimed design and delineated portions of the claimed design that are shown on an enlarged scale in FIGS. 9 and 10. The dashed broken lines in FIGS. 1, 2, 3, 8, and 9 depict portions of the LED saber that form no part of the claimed design.